100
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Is there Benefit for Cyp2C19 Genotype-Guided Antiplatelet Treatment in Elderly Acute Coronary Syndrome Patients?

ORCID Icon & ORCID Icon
Pages 727-730 | Received 22 Jun 2021, Accepted 26 Jun 2021, Published online: 12 Jul 2021
 

Financial & competing interests disclosure

JM ten Berg reports grants from the Netherlands Organization for Health Research and Development, a Dutch government institution called ZonMw. JM ten Berg reports speaker fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, the Medicines Company, Accumetrics, Boehringer-Ingelheim, Bayer, BMS, Pfizer and Ferrer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

JM ten Berg reports grants from the Netherlands Organization for Health Research and Development, a Dutch government institution called ZonMw. JM ten Berg reports speaker fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, the Medicines Company, Accumetrics, Boehringer-Ingelheim, Bayer, BMS, Pfizer and Ferrer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.